Horizon Investments’s Summit Therapeutics SMMT Stock Holding History

Horizon Investments’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28	Closed	-$531	–	1488
2026 Q1	$531	Buy	+28	New	+$453	﹤0.01%	1363

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Horizon Investments's SMMT Position: Q2 2026 in Review

Horizon Investments sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 28 shares — an estimated $531 sold.

Horizon Investments first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $531 in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Horizon Investments reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Horizon Investments sold 28 Summit Therapeutics shares in Q2 2026, an estimated $531.
Horizon Investments first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
Horizon Investments's Summit Therapeutics position peaked at $531 in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.